Trials / Completed
CompletedNCT03273660
Evaluation of the Re-volumizing Performance of Aliaxin (New Trademark)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Derming SRL · Academic / Other
- Sex
- Female
- Age
- 40 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Aim of the study is to evaluate the re-volumizing performance and the duration effect of the product Aliaxin (new trademark) in women aged 40-65 years with midface volume defects due to aging mechanism.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.) | First treatment was performed during baseline visit, after the basal evaluations planned by the study procedure. 0.5-1.1 ml of Aliaxin (new trademark) for emi-face was injected by needle (25-27 G) and/or cannula (25 G, 40 mm). A touch-up treatment (0.5-1.1 ml of Aliaxin new trademark for subject) was performed after 3-4 weeks (T1) in order to treat possible asymmetry. |
Timeline
- Start date
- 2017-06-05
- Primary completion
- 2018-03-13
- Completion
- 2018-03-13
- First posted
- 2017-09-06
- Last updated
- 2018-07-27
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT03273660. Inclusion in this directory is not an endorsement.